

William G Ondo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/521749/publications.pdf>

Version: 2024-02-01

53
papers

3,608
citations

147801
31
h-index

161849
54
g-index

57
all docs

57
docs citations

57
times ranked

2460
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring the Relationship Between Parkinson Disease and Restless Legs Syndrome. Archives of Neurology, 2002, 59, 421.	4.5	355
2	Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Movement Disorders, 2005, 20, 958-963.	3.9	281
3	Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: A possible model for restless legs syndrome?. Movement Disorders, 2000, 15, 154-158.	3.9	250
4	A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology, 2004, 62, 37-40.	1.1	223
5	Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism and Related Disorders, 2008, 14, 28-32.	2.2	183
6	Olanzapine treatment for dopaminergic-induced hallucinations. Movement Disorders, 2002, 17, 1031-1035.	3.9	179
7	Reliability of a new scale for essential tremor. Movement Disorders, 2012, 27, 1567-1569.	3.9	159
8	Methadone for refractory restless legs syndrome. Movement Disorders, 2005, 20, 345-348.	3.9	142
9	Gabapentin for essential tremor: A multiple-dose, double-blind, placebo-controlled trial. Movement Disorders, 2000, 15, 678-682.	3.9	138
10	Ropinirole for restless legs syndrome. Movement Disorders, 1999, 14, 138-140.	3.9	115
11	Sodium Oxybate for Excessive Daytime Sleepiness in Parkinson Disease. Archives of Neurology, 2008, 65, 1337-40.	4.5	114
12	Long-term Treatment of Restless Legs Syndrome With Dopamine Agonists. Archives of Neurology, 2004, 61, 1393.	4.5	95
13	Intrathecal baclofen for dystonia. Movement Disorders, 2001, 16, 1201-1202.	3.9	90
14	Tetrabenazine Treatment for Huntington's Disease-Associated Chorea. Clinical Neuropharmacology, 2002, 25, 300-302.	0.7	80
15	The North American Survey of Placement and Adjustment Strategies for Deep Brain Stimulation. Stereotactic and Functional Neurosurgery, 2005, 83, 142-147.	1.5	74
16	Bruxism in Huntington's disease. Movement Disorders, 2000, 15, 171-173.	3.9	67
17	Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Medicine, 2010, 11, 494-496.	1.6	61
18	Onabotulinum toxin-A injections for sleep bruxism. Neurology, 2018, 90, e559-e564.	1.1	58

#	ARTICLE	IF	CITATIONS
19	Predictors of battery life for the Activa® Solettra 7426 Neurostimulator. Parkinsonism and Related Disorders, 2007, 13, 240-242.	2.2	56
20	Association between restless legs syndrome and essential tremor. Movement Disorders, 2006, 21, 515-518.	3.9	51
21	Memantine for non-motor features of Parkinson's disease: A double-blind placebo controlled exploratory pilot trial. Parkinsonism and Related Disorders, 2011, 17, 156-159.	2.2	50
22	Vascular parkinsonism: Clinical correlates predicting motor improvement after lumbar puncture. Movement Disorders, 2002, 17, 91-97.	3.9	48
23	Olfaction testing in patients with tremor-dominant Parkinson's disease: Is this a distinct condition?. Movement Disorders, 2005, 20, 471-475.	3.9	47
24	Hyperglycemic nonketotic states and other metabolic imbalances. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 100, 287-291.	1.8	44
25	Rheumatologic serologies in secondary restless legs syndrome. Movement Disorders, 2000, 15, 321-323.	3.9	40
26	Selegiline Orally Disintegrating Tablets in Patients With Parkinson Disease and "Wearing Off" Symptoms. Clinical Neuropharmacology, 2007, 30, 295-300.	0.7	37
27	Computerized posturography balance assessment of patients with bilateral ventralis intermedius nuclei deep brain stimulation. Movement Disorders, 2006, 21, 2243-2247.	3.9	36
28	Comparison of Weight Gain in Treatments for Tourette Syndrome: Tetrabenazine Versus Neuroleptic Drugs. Journal of Child Neurology, 2008, 23, 435-437.	1.4	35
29	Restless Legs Syndrome. Neurologic Clinics, 2009, 27, 779-799.	1.8	33
30	A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Movement Disorders, 1999, 14, 664-668.	3.9	32
31	Thalamic deep brain stimulation: Effects on the nontarget limbs. Movement Disorders, 2001, 16, 1137-1142.	3.9	32
32	Subthalamic deep brain stimulation in patients with a previous pallidotomy. Movement Disorders, 2006, 21, 1252-1254.	3.9	32
33	Zonisamide for Essential Tremor. Clinical Neuropharmacology, 2007, 30, 345-349.	0.7	29
34	An Open-Label Pilot Study of Levetiracetam for Essential Tremor. Clinical Neuropharmacology, 2004, 27, 274-277.	0.7	28
35	Restless legs syndrome. Current Neurology and Neuroscience Reports, 2005, 5, 266-274.	4.2	28
36	Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Movement Disorders, 2003, 18, 683-685.	3.9	26

#	ARTICLE	IF	CITATIONS
37	Withdrawal of visual feedback improves micrographia in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 2130-2131.	3.9	26
38	Restless Legs Syndrome. <i>Neurologic Clinics</i> , 2005, 23, 1165-1185.	1.8	23
39	Evaluating factors that can influence spirometry ratings in patients with essential tremor. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 45-48.	2.2	22
40	Essential tremor: Treatment options. <i>Current Treatment Options in Neurology</i> , 2006, 8, 256-267.	1.8	22
41	A Pilot Study of Botulinum Toxin A for Headache in Cervical Dystonia. <i>Headache</i> , 2005, 45, 1073-1077.	3.9	21
42	Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-blind, double-blind, double-dummy, placebo-controlled, crossover trial. <i>Movement Disorders</i> , 2010, 25, 2724-2727.	3.9	21
43	Apomorphine injections: Predictors of initial common adverse events and long term tolerability. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 619-622.	2.2	21
44	Physiological assessment of paroxysmal dystonia secondary to subacute sclerosing panencephalitis. <i>Movement Disorders</i> , 2002, 17, 154-157.	3.9	20
45	VIM deep brain stimulation does not improve pre-existing restless legs syndrome in patients with essential tremor. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 113-114.	2.2	19
46	Intravenous flumazenil for Parkinson's disease: A single dose, double blind, placebo controlled, cross-over trial. <i>Movement Disorders</i> , 2006, 21, 1614-1617.	3.9	16
47	Tetrabenazine Treatment for Stereotypies and Tics Associated With Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2012, 24, 208-214.	1.8	13
48	Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 117-118.	2.2	11
49	Tremor Research Group Essential Tremor Rating Scale (TETRAS): Assessing Impact of Different Item Instructions and Procedures. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 10, 36.	2.0	10
50	Essential Tremor. <i>CNS Drugs</i> , 1996, 6, 178-191.	5.9	9
51	TETRAS Spirals and Handwriting Samples: Determination of Optimal Scoring Examples. <i>Tremor and Other Hyperkinetic Movements</i> , 2021, 11, 50.	2.0	3
52	Gait and balance disorders. <i>Medical Clinics of North America</i> , 2003, 87, 793-801.	2.5	1
53	The straight dope on addiction to dopamimetic drugs. <i>Movement Disorders</i> , 2002, 17, 223.	3.9	1